Company profile
IMMUNOVANT, INC.
NASDAQ:IMVTBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BATOCLIMAB | phase3 | — | 10 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (19)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07286006 | phase2 | enrolling_by_invitation | 2026-01-26 | 2030-03-01 | Immunovant Sciences GmbH | A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD) |
| NCT05907668 | phase2 | completed | 2023-05-15 | 2025-07-25 | Immunovant Sciences GmbH | A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease |
| NCT03863080 | phase2 | completed | 2019-05-21 | 2020-10-07 | Immunovant Sciences GmbH | A Study of RVT-1401 in Myasthenia Gravis (MG) Patients |
| NCT07018323 | phase2 | recruiting | 2025-06-19 | 2027-05-01 | Immunovant Sciences GmbH | A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease |
| NCT06727604 | phase2 | recruiting | 2024-12-17 | 2028-06-01 | Immunovant Sciences GmbH | A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease |
FDA applications (0)
No records yet.